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Sammendrag
Tittel: Fungal products and inflammatory responses in human monocytes and 
epithelial cells
Norsk tittel: 
Virkningen av muggsoppkomponenter på immunforsvaret hos mennesker – 
reaksjoner fra lunge- og blodceller
Muggsopp i innemiljø kan forårsake flere ulike symptomer hos mennesker som 
eksponeres. De vanligste reaksjonene ligner betennelsesreaksjoner i slimhinner, særlig 
i øvre luftveier, men også andre symptomer slik som hodepine, kvalme, unormal 
trøtthet, konsentrasjonsvansker (”tung i hodet”) og eksem kan være vanlige. Personer 
med astma er særlig utsatt for inneklimarelaterte plager, men det er hittil ukjent 
hvorfor disse personene er særlig utsatt. Til tross for mye fokus på allergiske 
reaksjoner på grunn av eksponering for muggsopp, er det sjeldent at mennesker får 
allergiske reaksjoner pga muggsopp sett i fra et immunologisk perspektiv. Det er 
imidlertid grunn til å tro at andre typer reaksjoner fra immunforsvaret (ikke-
allergiske) kan være mer aktuell. Det er holdepunkter for at stoffer/komponenter som 
muggsopp produserer er viktige bidragsytere for reaksjoner.
I tillegg til en rekke andre komponenter som muggsopp produserer, er muggsoppgifter 
(mykotoksiner) særlig aktuelle. Doktorgradsarbeidet har i hovedsak fokusert på 
hvordan celler i immunforsvaret reagerer når de blir utsatt for særlig små doser av 
disse giftene, noe som kan være situasjonen ved forurensing av muggsopp innendørs. 
Det er i hovedsak vist at muggsoppgifter bidrar til å forstyrre cellenes produksjon av 
ikke-allergiske signalstoffer (inflammatoriske cytokiner). På denne måten kan det 
oppstå en ubalanse i immunforsvaret slik at sjansen for betennelsesreaksjoner kan 
øke. De påviste cellereaksjonene kan muligens ha betydning for noen av de opplevde 
symptomene som relateres til muggsopp i innemiljø. Det er også vist i et delarbeid at 
komponenter fra muggsopp kan bidra til å frembringe spesielle reaksjonsmønster hos 
astmatikere sammenliknet med ikke-astmatikere, og dette kan indikere/dokumentere 
at immunresponsen hos astmatikere faktisk er forskjellig sammenliknet med 
reaksjonen hos ikke-astmatikere. Dette delarbeidet kan være begynnelsen på den 
videre dokumentasjonen av helseplager som astmatikere kan oppleve på grunn av 
muggsopp i innemiljø.       
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71 Introduction 
1.1  Environmental microbes and associations to negative health effects 
Negative health effects due to environmental microbes have been described and known to 
people for centuries. In the 1833, collections and descriptions of environmental microbes were 
shown in Ehrenberg’s Illustrations of Dust collected by Charles Darwin. Later, Pasteur and co-
workers developed theories which associated many airborne environmental microbes directly to 
the development of human disease. This led to systematic research on various microbes present in 
food, water and in the air and the human health effects of this microbial exposure (Lacey and 
West, 2006).  
Throughout the last century, an increasing number of publications have reported 
symptoms experienced by individuals living or working in modern buildings with poor indoor air 
quality (IAQ). In the early 1980’s the concept of sick building syndrome (SBS) emerged 
(Finningan et al., 1984). SBS, or in recent years called building-related symptoms (BRS), has 
been characterised as symptoms related to environmental exposure (sometimes of unknown 
origin) in a building that is experienced by otherwise healthy individuals. The symptoms can be 
associated with effects on multiple organ systems and includes respiratory symptoms, headaches, 
nausea, fatigue, concentration problems and dizziness (Hardin et al., 2003; Terr, 2004; 
Shoemaker et al., 2006). In view of the complexity of chemical, microbial and physical exposure 
agents in a modern building, the evidence that microbes are the (only) cause of SBS is missing 
(Kolstad et al., 2002).  
8The association between damp houses and SBS seems to be more established than the link 
between SBS and microbial exposure. However, the damp indoor environment may harbour a 
wide range of microorganisms including several kinds of environmental bacteria, such as gram-
negative species and their products such as endotoxins as well as mycobacteria, moulds and other 
fungi which together create the microbial exposure (Anderson et al., 1997). The health effects 
associated to damp buildings generally consist of upper respiratory tract complaints of 
inflammatory nature such as rhinitis, sinusitis, irritation of the mucous membrane, cough and 
cold-like symptoms (Mahmoudi et al., 2000; Fisk et al., 2007). Also, neurological associated 
symptoms such as headache, concentrations problems, fatigue and nausea have been reported 
(Pirhonen et al., 1996; Shoemaker and House, 2006). Reports of eczema (Bornehag et al., 2005) 
and fever (Pirhonen et al., 1996) are less common. Further, several reports of an increased 
prevalence of asthma symptoms in damp buildings with mould problems have been published 
(Taskinen et al., 1997; Taskinen et al., 1999; Engvall et al., 2001; Trout et al., 2001). In 
occupational settings, such as in the composting and waste-handling industry, in agricultural 
settings and during building demolition, exposure to high concentrations of airborne moulds is 
well known to induce negative health effects (Brun, 2007). 
Inhalation of airborne mould spores has in particular been associated with the aggravation 
of respiratory symptoms and asthma (Fisk et al., 2007; Hirvonen et al., 2005; Hope and Simon, 
2007; Nevalainen and Seuri, 2005). Asthma is a chronic hypersensitivity condition with 
inflammatory reactions and bronchial constriction. Asthma is traditionally classified as IgE-
mediated (extrinsic asthma or allergic/atopic asthma), non-IgE-mediated (intrinsic asthma or non-
allergic/non-atopic asthma) and in recent years also as a mixed form of the two types. Clinical 
symptoms in non-allergic asthma resemble those in allergic asthma, but the immune response 
9mechanisms are partially different (Comi et al., 2007). In general, however, fungi seem to cause 
symptoms of inflammation in both allergic and non-allergic asthma patients.  
Although, moulds possess potentially harmful properties, infections due to mould 
exposure are relatively rare. An increasing number of cases have been reported, however, 
primarily in hospitalised and critically ill patients with severe underlying illness (Khasawneh et 
al., 2006). In immune suppressed patients, fungal infections may be life threatening. Moulds such 
as Aspergillus, Fusarium, Scedosporium and Penicillium, and yeasts such as Candida and 
Cryptococcus are most frequently isolated from fungal infections (Enoch et al., 2006). 
A large amount of studies have associated mould exposure to various (non-allergic) 
symptoms of inflammation. Therefore, it seems warranted to investigate some of the cellular 
responses that may be involved in the symptoms experienced by individuals living or working in 
damp and mouldy buildings. 
  
1.2 The Kingdom Fungi 
Mycology, the study of fungi, has originated from botany as fungi earlier were considered 
members of the plant kingdom. Classification has now placed fungi in one of five eukaryotic 
kingdoms, the others being animals, plants, chromista and protozoa. Indeed, many fungi resemble 
plants in that they develop fruiting bodies and produce spores which disperse by air currents. The 
fruiting body of filamentous fungi is composed of long branching threads (hyphae) of 
multicellular filaments which are individually divided into smaller compartments and typically 
contain several nuclei. These compartments are fungal cells. The spores, or conidia, are often 
attached to specialised cells arising from the hyphae. Many filamentous fungi produce large 
networks of hyphae (when visible called mycel) and vast amount of spores. 
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The largest group of filamentous microscopic fungi (microfungi) is known as moulds. 
Moulds are ubiquitous in nature and are frequently found on decaying plants and in soil where 
they function as important organisms to regulate the ecosystem. Moulds are saprophytes that 
decompose and metabolise almost any kind of organic material. Also, moulds are closely 
associated with environmental bacteria and yeasts and compete with them for nutrition. In this 
setting, mycology is considered a branch of microbiology. 
Metabolites that are produced and secreted by many types of fungi, both moulds and 
yeasts, are often used in the food and brewing industry because fungi are easily grown in pure 
cultures with relatively high growth rates. Fungi may be used as sources to produce catalytic 
enzymes used in fermentation and in other biochemical processes (Baker, 2006). Many features 
of fungi have also made them attractive in research on fundamental biological processes such as 
the study of cellular energy metabolisms, genome studies, protein synthesis and expression, and 
in evolutionary and mutation research. In recent years, fungi have been frequently used as model 
organisms to study the structure and function of genes and gene products (Matsumoto and 
Ledbetter, 1999). 
Fungal cells produce a variety of metabolites due to primary and secondary metabolic 
processes (Carlile et al., 2001). Primary metabolites are produced as a result of cellular processes 
essential to maintain survival of the fungal cell, i.e. maintenance of the cell wall or energy 
metabolism. Secondary metabolites are largely not essential for the survival of fungal cells, 
although production of some secondary metabolites, such as toxins, may offer evolutionary 
advantages in the competition with other environmental microbes.  
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1.2.1 Cell composition of fungi and virulence factors 
Fungi are eukaryotic cells with intracellular compartments including endoplasmatic 
reticulum, Golgi apparatus, mitochondria and vacuoles used for transport and storage of 
nutrients. Fungal DNA is organised into a number of chromosomes. Several of the Aspergills sp. 
typically contains 8 chromosomes (Baker, 2006). The phospholipid bilayer and proteins in the 
cell membrane is covered by a rigid, but also elastic and dynamic cell wall consisting mainly of 
carbohydrates (polysaccharides) and structure proteins. Other proteins embedded in the cell wall 
are transport proteins and enzymes used in primary and secondary metabolism, and pigment 
molecules such as melanin (Fog-Nielsen, 2003; Horner et al., 1995; Bruneau et al., 2001; Jahn et 
al., 1997). Some of these proteins may be allergens. Generally, fungi produce a vast amount of 
metabolites that potentially may enhance their inflammagenic, allergenic and toxic properties. 
Fungi have through evolution adapted to handle almost any type of changing 
environment. Although survival is easy for most environmental fungi, the ideal condition for 
growth is a moderate temperature (20-30°C), a relatively high moisture environment and a high 
carbohydrate content of the growth substrate. Moulds such as Penicillium and Aspergillus are 
often found in small amounts in outdoor air and in a balanced mixture with other fungal genera 
such as Cladosporium, Mucor, Acremonium, Paecilomyces and many others. Some species, 
especially within the Aspergillus and Paecilomyces genera, have developed thermotolerant or 
thermophilic properties and are able to grow at 37°C and above. This feature is one of many 
virulence factors that could facilitate mould invasion in human tissues (Aufauvre-Brown et al.,
1998).  
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Molecules of the carbohydrate rich cell wall of fungi are thought to be involved in 
induction of inflammatory responses. The cell wall of fungi consists of several polysaccharide 
layers, mannosylated and glycosylated structure proteins, and small amounts of lipids (such as 
ergosterol) that together form a rigid skeleton providing strong physical properties (Carlile et al.,
2001). The inner polysaccharide layers consist mainly of glucose polymers (glucan), which 
occurs with α- and/or β- linkages (α-and β-glucans) and also relative small amount of chitin 
(Bernard and Latgé, 2001). Generally, glucans may appear with a relatively wide molecular 
weight range (from 7 to 500 kDa for some well characterised molecules) and with various 
degrees of branching (Barreto-Bergter et al., 1983). The biologically most active form of glucan 
found in fungi has a β-1, 3-D-glucan backbone. Various forms of soluble and particulate β-
glucans induce pro-inflammatory cytokines in human immune cells, such as IL-1, IL-2 and TNF-
α, both in vitro and in vivo (Rylander and Lin, 2000; Hohl et al., 2005; Taylor et al., 2007; Beijer 
et al., 2003; Sherwood et al., 1987, Sigsgaard et al., 2000).  
Glucans may be liberated to the environment from the cell wall of decomposed, 
fragmented or structurally damaged fungal cells and also during germination and growth when 
cell walls are recomposing (Hohl et al., 2005). The content of β-glucans in dust has been assessed 
(Giovannangelo et al., 2007) and the glucan content in samples of airborne or settled dust has 
been used as a surrogate measurement of moulds in the indoor environment (Schram-Bijkerk et 
al., 2005; Douwes et al., 1999).  
Although β-glucans have been a main subject of investigation in relation to symptoms 
experienced in mouldy buildings, most intact fungal cells and resting airborne conidia do not 
display large amounts of β- glucans on the outer surface (Gantner et al., 2005; Hohl et al., 2005). 
Other soluble extracellular polysaccharides (EPS) are present in the outer cell wall layer of i.e. A. 
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fumigatus, such as α-mannose polymers (mannan) supplemented with side chains of galactose or 
β-galactofuranose (called galactomannan) (Bernard et al., 2001; Latge, 2005). Important moulds 
found in the indoor environment such as species within the Aspergillus, Penicillium, 
Cladosporium, Stachybotrys and Trichophyton genera have largely similar composition of the 
cell wall structure (Leal et al., 1992; Ikuta et al., 1997; François et al., 2006; Latge, 1988). 
Galactomannan polysaccharides (Fig. 1) are covalently bound to mannosylated proteins on the 
cell wall surface (Fontaine et al., 2000; Bernard et al., 2001). Earlier, this mannan coat has been 
thought to be biologically inert and mask the immune stimulating properties of the glucan layer 
(Artursson et al., 1987). However, recently it has become evident that mannan polysaccharides 
are recognised by cell surface receptors on monocytes and macrophages and induce inflammatory 
cytokine responses such as TNF-α production (Netea et al., 2006; Netea et al., 2006). This 
understanding has opened up for the possibility that intact and non-sporulating fungal conidia 
may induce inflammatory responses without fungal growth in the host.  
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Fig 1. A tentative scheme of the organization of the β-1, 3-glucan and its covalently associated polymers 
found in the cell wall of A. fumigatus. The polysaccharide network is formed by (i) biosynthesis of the 
individual polysaccharides (β-1, 3-glucan, β-1, 3/1, 4 glucan, chitin, and galactomannan), (ii) branching of 
β-1, 3-glucan and increasing the number of acceptor sites, and (iii) covalent addition of chitin, 
galactomannan and β-1, 3/1, 4-glucan to glucan branches (Fontaine et al., 2000). 
1.3 Mycotoxins 
Secondary metabolites produced by fungi include the mycotoxins. Mycotoxins are a large 
group of several hundred (over 400 are described) chemically distinct organic compounds 
synthesised through secondary metabolic pathways in the fungi. Some mycotoxins are amongst 
the most toxic biological compounds known. 
Health effects of mycotoxins are dependent of the time and dose of exposure, the route of 
administration (oral/dermal/inhalation), the toxic effects on specific cells/organs, the health status 
of the individual and possibly the co-effects with other chemicals to which the individual is 
exposed (Bennett and Klick, 2003). Exposure to high concentrations of mycotoxins may cause a 
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wide range of health effects, from short-term and immediate toxic ones to long-term mutagenic 
and carcinogenic ones (Peraica et al., 1999).  
In relation to poisoning and carcinogenicity the oral route of mycotoxin exposure is the 
most common, but also dermal routes may be involved. The toxic effects of mycotoxins have 
been recognised since the medieval times. Ergotamine (ergot alkaloids) produced by the mould 
Claviceps purpurea on contaminated rye caused thousands of deaths in both animals and humans 
due to ergot poisoning, known as St. Anthony’s fire. In 1777 in France, 8,000 people died of 
gangrenous ergotism. Even today, aflatoxin, produced by Aspergillus flavus on many agricultural 
products, constitutes a major problem because of contamination of food and feed, especially in 
developing countries. In recent years, however, quantitative standards and guidelines to avoid 
negative health effects from consumption of contaminated foods and feeds have been established 
throughout the world for the most potent mycotoxins such as aflatoxin, ochratoxin, 
trichothecenes and fumonisins. 
Although mycotoxins are of concern to humans and animals, many beneficial effects have 
been appreciated. Possibly the most important benefits of mycotoxins were established through 
the discovery of penicillin in the 1930’s. This was a breakthrough for medical research and in the 
treatment of infections. Later, many types of mycotoxins have been investigated and used for e.g. 
their antibiotic effects.
Mycotoxins are produced during the late log-phase of fungal growth and probably when 
they may be beneficial for the fungi in order to compete with other microbes in the environment 
(Calvo et al., 2002). Mycotoxin production is often associated with certain fungal species, but 
several mycotoxins may be produced by one single species and one single mycotoxin may be 
produced by several different species (Table 1). Also, different strains within the same species 
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have shown to produce various types of mycotoxins (Fog-Nielsen, 2003) suggesting that toxin 
production is dependent on environmental growth conditions such as the carbon and nitrogen 
source, temperature, light and pH (Bennett and Ciegler, 1983). 
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Table 1. Indoor air fungi and associated mycotoxins (modified from Abbott, 2002). 
Acremonium
Alternaria 
Arthrinium 
Aspergillus 
Bipolaris
Chaetomium 
Cladosporium 
Fusarium
Gliocladium 
Paecilomyces 
Penicillium 
Phoma
Rhizopus
Sclerotinia 
Stachybotrys
Trichoderma
Trichothecium
Wallemia
Zygosporium
citrinin 
altenuene, altenusin, alternariol, altertoxin, 
tenuazonic acid 
nitropropionic acid 
aflatoxin, austin, citrinin, cytochalasin, fumitoxin, 
nidulotoxin, ochratoxin, patulin, sterigmatocystin,
gliotoxin, fumitremorgen, penitrem, territrem, 
verruculogen, viomellein, vioxanthin, 
xanthomegnin 
cytochalasin, sporidesmin, sterigmatocystin 
chaetoglobosin, chetomin, chaetochromin, 
chaetosin, cochliodinol, sterigmatocystin 
cladosporic acid 
fumonisin, fusaric acid, fusarin, 
fusarochromanone, moniliformin, trichothecenes 
(deoxynivalinol, T2 toxin), zearlenol, 
zearalenone 
gliotoxin 
patulin, viriditoxin 
citrinin, citreoviridin, citromycetin, erythroskyrin, 
ochratoxin, gliotoxin, griseofulvin, luteoskyrin, 
oxaline, patulin, penicillic acid, roquefortine, 
rubratoxin, rugulosin, rugulovasine, penitrem, 
territrem, verruculogen, verrucosidin, viomellein, 
viridicatin, xanthomegnin 
brefeldin, cytochalasin, secalonic acid, tenuazonic 
acid 
rhizonin 
furanocoumarins 
griseofulvin, trichothecenes (isosatratoxin, 
roridin, satratoxin, trichodermol, trichoverrol) 
gliotoxin, koninginin, trichodermin 
roseotoxin, trichothecenes (trichothecin) 
walleminol 
cytochalasin 
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In the indoor environment, mycotoxins have been isolated from spores, hyphal fragments 
and fungal particulates as well as in dust, bioaerosols and in building materials (Fog-Nielsen, 
2003; Tuomi et al., 2000). Some recent experimental studies suggest that mycotoxins may 
adversely affect biological processes and in particular modulate immune responses, e.g. the 
production of cytokines involved in inflammation (Chung et al., 2003; Pestka et al., 2006; 
Theumer et al., 2003; Islam and Pestka, 2006). Although pulmonary mycotoxicosis in humans 
due to inhalation of toxic mould spores has been reported in a few case studies, e.g. during the 
cleaning of silos (Perry et al., 1998), it has not been described in an ordinary indoor air context. 
Nevertheless, it is a general problem that safe exposure limits with regard to inhaled mould 
spores and mycotoxins have not been established. This has raised concerns among individuals 
living or working in mouldy environments. 
1.3.1 Gliotoxin 
Gliotoxin is an epipolythiodioxopiperazine (ETP) secondary metabolite of about 326 Da 
traditionally known to be cytotoxic and to induce dose-dependent apoptosis or necrosis in 
prokaryotes and eukaryotes (Kamei and Watanabe, 2005). Gliotoxin has been isolated from fungi 
such as Aspergillus sp., Penicillium sp., Gliocladium sp. and Trichoderma sp. (Table 1). The 
biologically active form of gliotoxin is oxidised with an intact disulfide bridge (Fig.2).
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Fig 2. Chemical structures of gliotoxin (Bernardo et al., 2003) 
 Uptake of gliotoxin in target cells initiates an intracellular red-ox reaction that reduces the 
di-sulfide form (oxidised) of the molecule to the inactive di-thiol form (reduced) by a mechanism 
that is dependent on the intracellular antioxidant glutathione (Bernardo et al., 2003). This 
suggests that gliotoxin may be involved in cellular oxidative stress mechanisms. Gliotoxin in 
cytotoxic doses have been studied, and in this setting the mycotoxin has been regarded as an 
immunosuppressive compound that reduces inflammation by inducing cellular apoptosis (López-
Franco et al., 2002). However, the cellular effects of non-cytotoxic doses of gliotoxin in relation 
to inflammation have not been well investigated.  
1.3.2 Citrinin 
Citrinin was first isolated from Penicillium citrinum (Hetherington and Raistrick, 1931) and the 
chemical structure was proposed (Fig. 3). The mycotoxin is a 250 Da organic compound 
produced by fungal genera including Aspergillus, Penicillium and Acremonium. It is known to be 
nephrotoxic by inducing dose-dependent apoptosis or necrosis in kidney tissue (Clark et al., 
2006; Bennett and Klich, 2003). The cellular mechanisms that induce cell death upon citrinin 
 di-sulfide form (oxidised)          di-thiol form (reduced)           bis-metyl-thioeter form           di-prolyl ETP  
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exposure are not fully known. The electron transport systems in mitochondria have been 
suggested as a target of the toxic action of citrinin (Da Lozzo et al., 1998). However, recent 
investigations using DNA microarray technology have also suggested that induction of oxidative 
stress genes and interference with the antioxidant glutathione in the target cell also may be 
involved (Iwahashi et al., 2007). In vivo studies have suggested that citrinin may contribute to 
inflammatory responses after oral consumption (Hanika et al., 1986). However, effects of low 
concentrations, or non-toxic doses, in relation to inflammatory responses in immune cells or cells 
of the respiratory mucosa have not been investigated.  
Fig. 3  Chemical structure of citrinin (Bennett and Klich, 2003) 
1.4 Bacterial endotoxin 
Endotoxins are compounds produced by many environmental as well as pathogenic gram-
negative bacteria. The endotoxins consist mainly of immune stimulating molecules of 
lipopolysaccharide (LPS) in which the lipid component is well known to induce inflammatory 
responses (Su et al., 1995). The host responds to LPS exposure by inducing an efficient 
inflammatory response with the production of pro-inflammatory mediators. Inhalation of elevated 
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concentrations endotoxin in the environment cause inflammatory cytokine production by cells in 
the bronchial and alveolar mucosa (Thorn, 2001). 
Clinical symptoms of endotoxin-induced inflammation in the lungs include bronchial 
hyperreactivity and fever. Exposure to endotoxin has also been associated with the aggravation of 
chronic inflammatory lung diseases, including asthma and chronic bronchitis (Michel et al.,
1992; Vernooy et al., 2002). 
In some indoor air environments, increased concentrations of endotoxins have been 
associated with a number of household factors, such as pets, floor cover, the amount of people 
living in the home and the efficiency of ventilation (Giovannangelo et al., 2007). Also, an 
elevated concentration of endotoxin-producing bacteria has been found in indoor environments 
with a general enhanced microbial flora (Schram et al., 2005).  
1.5 Important cells and mediators of the innate immune system 
1.5.1 Cells 
The innate immune system in mammalians is crucial for survival. The cellular immune 
response to invading microbes is primarily to kill the microbe and clear inflammation, 
alternatively to halt further invasion of microbes until an adaptive immune response with the 
production of antibodies can develop. Fig. 4 shows an overview of the time courses of innate and 
adaptive cellular responses to invading microbes. 
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Fig. 4
Cells and mediators involved in an innate and adaptive immune response to invading microbes (Adapted 
from www.actagainstallergy.com). 
The epithelial layer represents the first cellular barrier that prevents microbes from 
invading the host. Epithelial surfaces are important physical barriers, but the cells are also 
involved in defence mechanisms with a small production of inflammatory chemokines and 
cytokines (Takizawa, 1998). Monocytes, macrophages, granulocytes and dendritic cells are the 
most important cells in innate immune defence for the recognition and uptake (phagocytosis) of 
pathogens. Receptors on monocytes and macrophages are specialised to recognise characteristics 
of microbial surfaces, such as evolutionally preserved pathogen-associated molecular patterns 
(PAMP). The specialised pathogen recognition receptors (PRR) include the Toll-like receptors 
(TLR) and members of the C-Lectin super family. When receptors recognise microbes, cell 
activation and a subsequent release of inflammatory mediators, such as cytokines, may proceed.
Cytokines produced by activated monocytes and macrophages further affect the immune response 
in many ways, both locally and systemically.  
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1.5.2 Inflammatory cytokines  
A number of important cytokines and chemokines are produced by activated innate 
immune cells in response to receptor binding of a trigger agent. The following cytokines are of 
special interest in the mediation of inflammatory responses and is dealt with in this thesis.  
The most abundant pro-inflammatory cytokine produced in early stages of an 
inflammatory response is tumour necrosis factor-α (TNF-α) discussed elsewhere in this thesis. 
Further, IL-12p70 have dual roles in both being pro-inflammatory and in skewing the innate 
immune response towards an adaptive response with the subsequent production of antibodies, 
e.g. IL-12p70 modulate an IgE-mediated immune response to various allergens (Kim et al., 
1997). Also, the pleiotrophic cytokine IL-6 is mainly known to be involved in pro-inflammatory 
responses of the innate immune system, but also as a connector to the adaptive immune system 
by being involved in cell proliferation of lymphocytes and antibody production. The chemokine 
IL-8 has a primary role of being a granulocyte attractant to recruit other inflammatory cells to the 
site of an infection.  
The anti-inflammatory cytokines transforming growth factor-β (TGF-β) and IL-10 are 
important mediators in order to terminate or halt an inappropriate pro-inflammatory cytokine 
response initiated by e.g. TNF-α (Chung, 2001; Saxena et al., 2008). Although less is known 
about anti-inflammatory regulation within the cell, the beneficial effects of regulative cytokines 
have been proposed, e.g. TGF-β has been suggested in treatment of autoimmune diseases 
(Prud'homme et al., 2000). However, the fact that high TGF-β levels has a role in tumour 
progression (Medicherla et al., 2007), development of organ damage (Saxena et al., 2008) and 
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also in the aggravation of asthma (Duvernelle et al., 2003) suggest that increased TGF-β levels 
could be responsible for several negative health effects.  
1.5.3 Inflammatory cytokines and apoptosis  
Inflammatory cytokines play major roles in the regulation of apoptotic cell death. 
Apoptosis is a useful process for the healthy organism in order to eliminate highly activated or 
damaged cells and to resolve inflammatory processes in order to seal off damaged tissues and 
limit prolonged inflammation (Savill et al., 1997). The cytokines dealt with in this thesis are all 
connected to apoptotic processes within the cell.  
Briefly, TNF-α initiates cell death through TNF-receptor mediated apoptosis (Van der 
Meide et al., 1996; Chen et al., 2002). The pleiotropic cytokine IL-6 has been shown to play a 
role in apoptosis especially by participating in the regulation of inflammation (Hodge et al.,
2002). TGF-β production has been shown increase just prior to a TGF-β dependent apoptotic 
process (Hodge et al., 2002; Freire-de-Lima et al., 2006). Finally, increased IL-10 production has 
been shown to subsequently inhibit apoptotic processes (Zhou et al., 2001; Eslick et al., 2004).  
1.5.4 Mannan-binding lectin (MBL) 
The involvement of many types of serum/plasma proteins is of vital importance in the 
innate host defence. Acute phase proteins are associated with inflammatory responses and several 
are able to bind to microbes in order to facilitate recognition by receptors on phagocytic cells. 
One important acute-phase protein is the mannan-binding lectin (MBL) which recognises specific 
PAMP’s such as mannose residues on a wide range of microbes including viruses, bacteria, fungi 
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and protozoa (Janeway et al., 2005; Turner et al., 1998). MBL-microbe complexes activate the 
complement system through the MBL pathway (Fig. 5).
Fig 5 
Complement pathways in innate immune responses (Janeway et al., 2005). 
MBL deficiency in humans mainly results from one or several mutations in MBL genes 
and is primarily associated with increased susceptibility to infections and some autoimmune 
diseases (Garred et al., 2001). Recently, a link between high serum MBL concentrations and 
certain inflammatory diseases, such as childhood asthma, has been proposed (Uguz et al., 2005). 
However, the physiological role of high MBL concentrations in asthma is not well understood. 
MBL has also been investigated in relation to pro-inflammatory cytokine production and it has 
been suggested that microbes with highly mannosylated surfaces induce lower levels of pro-
inflammatory cytokines from monocytes in the presence of high MBL concentrations, while pro-
inflammatory cytokine production is enhanced in the presence of low MBL concentrations (Jack 
et al., 2001). Further, some authors report that the production of regulatory and anti-
inflammatory cytokines, such as IL-10, is enhanced in the presence of high MBL concentrations 
(Fraser et al., 2006). This suggests that circulating MBL may be involved in modulation of 
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inflammatory cytokine responses and possibly plays an important role in the progression and 
severity of inflammatory diseases.
1.6 Oxidative stress and glutathione 
Adverse cell damage caused by the exposure to oxidative agents, e.g. reactive oxygen 
species (ROS), is commonly referred to as oxidative stress. Many oxidising compounds may be 
harmful to the cell as they bind to negatively charged intracellular molecules such as DNA and 
proteins. Binding of oxidants to DNA may induce mutagenic or carcinogenic effects in the cell, 
while proteins or lipids may alter their functions when bound to or influenced by oxidative 
agents.  
Host defence mechanisms against oxidative agents involve the action of intracellular 
antioxidants present in all healthy cells. One important antioxidant is glutathione. Glutathione is 
typically used as a term to refer to tripeptide L-gamma-glutamyl-L-cysteinyl glycine in both its 
reduced and oxidised form (López-Mirabal and Winther, 2007). 
The reduced form of glutathione is N-N-L-gamma-glutamyl-L-cysteinyl glycine (GSH) 
while the oxidised form of glutathione is L-gamma-glutamyl-L-cysteinyl glycine disulfide 
(GSSG). GSH is involved in many catalytic and metabolic processes in the cell, in signal 
transduction, gene expression and regulation of apoptosis (Anderson, 1998; Higuchi, 2004; 
Franco et al., 2007). In the normal situation of low cellular oxidative stress the GSH/GSSG ratio 
is close to 1. The enzyme glutathione reductase (GR), together with the co-factor nicotinamide 
adenine dinucleotide phosphate (NADPH), maintains glutathione in its reduced form (Griffith, 
1999). The reduction, or neutralisation, of oxidative agents by GSH is mainly catalysed by the 
enzyme glutathione peroxidase (GP). During this process the unstable and highly reactive 
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oxidised glutathione, GSSG, is formed. GSSG is then reduced to GSH by GR in order to 
maintain the high GSH pool in the cell (Anderson, 1998).
1.6.1 The link between glutathione and inflammatory cytokines 
Production of pro-inflammatory cytokines is a redox-sensitive process and the red-ox 
equilibrium is influenced by cytokine production and vice versa (Haddad et al., 2002; Haddad 
and Land, 2002). For example, GSH depletion activates inflammatory signals in the cell and the 
subsequent release of pro-inflammatory cytokines such as IL-1, IL-6 and TNF-α from alveolar 
epithelial cells (Haddad, 2000). Also, increased GSH levels have shown to inhibit pro-
inflammatory cytokine production in vitro and in some clinical trials (Pena et al., 1999). Less is 
known about the effect of GSH on anti-inflammatory cytokines, such as TGF-β and IL-10. Some 
studies have indicated that TGF-β may inhibit GSH synthesis (Arsalene et al., 1997; Jardine et 
al., 2002) suggesting that regulatory cytokines also may also influence, or be influenced by, the 
cellular red-ox state.  
1.6.2 The role for glutathione in host defence against mycotoxins  
The role for GSH is primarily to neutralise oxidative compounds by providing reducing 
equivalents, but GSH is also known to form temporary conjugates with oxidative agents. This 
mechanism has been suggested for some mycotoxins, i.e. depletion of the intracellular GSH pool 
is presumably caused by the formation of conjugates between GSH and the mycotoxin (Pfeiffer 
et al., 2005; Dai et al., 2002). Although this process is not well understood, it is thought that 
glutathione-transferases (GST), a family of multifunctional enzymes, catalyse this conjugation 
resulting in GSH-conjugates which are transported out of the cell. The export of GSH-conjugates 
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from cells is an ATP-dependent process mediated by proteins belonging to the multidrug-
resistance protein family (MRP). Proteins of the MRP family are also known as GSH-conjugate 
pumps (Cole et al., 2006).
Whether mycotoxins contribute to inflammatory responses through their interaction with 
GSH is poorly investigated. Mycotoxins often do not contribute directly to increase pro-
inflammatory cytokine production, but rather modulate or decrease cytokine production induced 
by other inflammatory compounds such as LPS (Chung et al., 2003). However, the involvement 
of mycotoxins in both oxidative stress mechanisms and in the modulation of inflammatory 
cytokine production seems plausible as summarised in Fig. 6, and discussed in this thesis. 
Mycotoxin
Oxidative stress
Cytokines
Inflammation
Papers 1,2,3
Paper 2
Fig. 6 Possible roles for a mycotoxin as a mediator of inflammation 
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2 Aims of the study
In view of the literature describing adverse health effects in humans as a result of fungal exposure 
and the lack of known responsible molecular and immunological mechanisms, it is important to 
elucidate some of the cellular responses that could be involved. The role of fungal compounds in 
relation to inflammatory responses is of particular interest. 
 The objectives of this thesis were as follows: 
• Determine time- and dose-effects of the mycotoxins citrinin and gliotoxin on 
inflammatory cytokine production in monocytes (paper I). 
• Elucidate the ability of the mycotoxins citrinin and gliotoxin to affect cellular oxidative 
stress mechanisms and to modulate inflammatory cytokine production in alveolar 
epithelial cells (paper II).  
•  Determine the effects of mixed microbial compound exposure and detect possible 
interactions between the compounds that could influence inflammatory cytokine 
production by monocytes (paper III).  
• Measure inflammatory cytokine production by monocytes from asthmatic individuals 
after in vitro exposure to fungal cell wall mannan polysaccharides and relate the cytokine 
production to autologous plasma mannan-binding lectin concentrations (paper IV).   
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3 Summary of papers 
Paper I 
Mycotoxins are present on airborne fungal spores and fragments and may possibly play a 
role in adverse health effects. In paper I we measured inflammatory cytokine production from a 
monocytic cell line (MM6) and elucidated time-and dose-effects of the mycotoxins citrinin or 
gliotoxin. Non-toxic mycotoxin concentrations reduced LPS-induced production of the regulatory 
and anti-inflammatory cytokine IL-10 while TNF-α production was not reduced. The reduced IL-
10 production was not caused by a general cytotoxic effect, as cell death by apoptosis did not 
increase. Reduced IL-10 production by the mycotoxins could support an inappropriate 
inflammatory response driven by TNF-α. LPS-induced IL-6 production was slightly influenced 
by the mycotoxins, but not to the same extent as IL-10 production. We conclude that the 
mycotoxins citrinin or gliotoxin cause an imbalance in inflammatory cytokine production in 
vitro. We propose from this study that exposure to the investigated mycotoxins may influence or 
enhance an inflammatory response.   
Paper II 
Production of inflammatory cytokines and induction of cellular oxidative stress 
mechanisms could be influenced by mycotoxins. We showed in paper II that LPS-induced 
production of the regulatory and anti-inflammatory cytokine TGF-β by an alveolar epithelial cell  
line (A549) was somewhat reduced when exposed to relatively low concentrations of the 
mycotoxins citrinin or gliotoxin. TGF-β production increased when cells were exposed to higher 
mycotoxin concentrations. Production of the pleiotropic cytokine IL-6 and the chemokine IL-8 
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was not affected. Levels of the antioxidant glutathione were reduced in A549 with increasing, but 
non-toxic concentrations of citrinin after 48 or 72 hrs. Dose-and time effects of mycotoxin 
exposure were also indicated by a tendency to an opposite relationship between TGFβ production 
and glutathione levels. We conclude that the investigated mycotoxins may induce cellular 
oxidative stress responses by reducing intracellular levels of the antioxidant glutathione and also 
modulate production of the regulatory and anti-inflammatory cytokine TGF-β.  
Paper III 
Exposure to combinations of microbial compounds (bacterial LPS, fungal polysaccharides 
and mycotoxin) may occur simultaneously in environmental exposure situations, but the cellular 
responses to such are poorly studied and not well understood. With different exposure regimes 
we showed in paper III that the fungal polysaccharides mannan or β-glucan induced TNF-α
production, but not detectable IL-10 production in normal human monocytes. The mycotoxin 
citrinin reduced LPS-induced IL-10 production, but not the TNF-α production, thus confirming 
earlier observations from paper I.  
We statistically estimated interactions between the bacterial and fungal compounds and 
the influence on TNF-α production by monocytes. By using a multiple regression model (linear 
mixed model) we found that monocyte exposure to combinations of the fungal polysaccharides, 
β-glucan in particular, and LPS reduced TNF-α production compared to single compound 
exposures. We conclude that TNF-α production by monocytes due to combined microbial 
compound exposure may be different from that deducted from exposure to the single compounds.  
Paper IV 
Individuals with asthma are at risk of bronchial symptoms when exposed to airborne 
fungi. It seems that increased levels of the plasma protein mannan-binding lectin (MBL) play a 
32
role in severe asthmatic disease, although the role for MBL in mild and untreated adult asthma is 
poorly investigated. Also, MBL has been shown to be involved in modulation of inflammatory 
cytokine production.  
We conducted a pilot study and report in paper IV that in vitro exposure of monocytes to 
the fungal cell wall polysaccharide mannan, in the presence of autologous plasma, induced lower 
TNF-α production in cells isolated from adults with mild and untreated asthma compared to 
healthy controls. A tendency to increased plasma MBL levels in asthmatics was observed, 
although not statistically significant, suggesting that MBL levels may be associated to the 
severity of asthma. Results from this small study call for further investigations on the role of 
MBL in asthma and in particular on the role of MBL in modulation of non-allergic inflammatory 
cytokine production induced by the fungal polysaccharide mannan. 
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4 General discussion 
4.1 Methodological considerations 
4.1.1 In vitro assays and the extrapolation to human exposure  
Environmental exposures are most often highly complex and involve a variety of agents, i.e. 
microbes, microbial products, particles and chemicals. Time and route of the exposure may vary 
and there is also variability of individual responses and subjective symptoms. Hence, in vitro 
investigations of exposure effects may sometimes be of limited relevance to describe actual 
biological effects of single or multiple agents in the environment. Also, in vitro experimental 
studies, commonly using single types of cells, have limited relevance in describing complex local 
and systemic responses seen in tissues and whole organisms. Observed modulations and 
alterations of cellular responses due to defined exposures are sometimes difficult to relate to 
specific clinical symptoms. In order to obtain a more detailed understanding of biological effects 
due to factors present in the environment, however, in vitro assays are essential. With the 
increasing availability of techniques used to explore complex processes in cell biology, the in 
vitro approach is invaluable to help us understand processes in the individual cell. New emerging 
genomics and proteomics techniques will probably be of great importance for large scale 
screening of single and multiple effects of exposure agents, thus, mechanisms in host responses 
can be studied more thoroughly. Once a more complete picture of biological mechanisms is 
known, understanding of physiological processes can emerge.   
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4.1.2 Soluble substances versus particles  
The route of microbial exposure in an indoor air setting is through inhalation and it is 
commonly thought that inhalation of particles, such as fungal spores and other airborne 
fragments, leads to the distribution of inflammatory compounds into the lungs. Thus, in vitro
studies using particles coated with inflammatory compounds of interest, such as LPS or fungal 
polysaccharides, may be useful in order to simulate the inflammatory potential of bacteria or 
fungal spores, respectively. The initiation of an inflammatory response may proceed through 
different membrane receptors used by soluble or particulate forms of inflammatory substances 
(Flo et al., 2000). Also, an increased inflammatory cytokine response to particles, probably 
because of adjuvant effects, is often observed (Berntzen et al., 1998). However, dose-effects or 
interactions between various microbial compounds may be difficult to observe using particles, 
and moreover the inflammatory compounds are not always linked to particles/microbes in the 
environment, but rather the compounds may be airborne and are inhaled i.e. through aerosols 
(Wouters et al., 2006). Thus, it is meaningful to study the inflammatory potential of defined 
soluble compounds and in particular when the vehicles for the various compounds are not well 
defined as in the case when the compounds are separated from spores, fragments, dust particles or 
whole cell microbes.   
4.1.3 Cell lines versus primary cells  
Cell-specific differences in the production of inflammatory cytokines are essential for the 
innate immune response and also for disease pathogenesis. In vitro cell line systems offer highly 
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reproducible cellular responses and minimal loss of cell viability, which often is a problem with 
normal immune cells especially when prolonged exposures are required.  
However, cell lines may also differ considerably in the ability to produce inflammatory 
cytokines probably because of different cell specific signalling through activated receptors 
(Zughaier et al., 2005). The alveolar epithelial cancer cell line A549 (paper II) has shown to 
respond somewhat different from normal epithelial cells during e.g. virus infections (Wansley et 
al., 2005), although inflammatory cytokine production after environmental LPS exposure of 
normal lung epithelial cells or A549 is similar (Palmberg et al., 1998).  
Some commonly used monocytic cell lines, such as THP1, have shown not to respond 
with inflammatory cytokine production when exposed to various sources of endotoxins (LPS) 
compared to normal blood monocytes (Yamamoto et al., 2003). The fact that cell line responses 
may not always be representative for normal cell responses makes it necessary to additionally test 
exposure effects in normal cell systems. The monocytic cell line MM6 (paper I) showed similar 
cytokine responses to LPS stimulation as primary blood monocytes did (papers III and IV).  
Some recent in vitro studies have shown interactions between different types of cells, i.e. 
lung epithelial cells and alveolar macrophages, and some of the complicated cellular processes 
and interactions that exists are suggested (Rubovitch et al., 2007; Elizur et al., 2008). However, 
the primary limitation of all in vitro studies will still be that the results obtained are only relevant 
for certain experimental settings, and thus they are difficult to extrapolate directly to in vivo
situations.  
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4.1.4 Human immune and epithelial cells as exposure targets in vitro 
  
Alveolar epithelial cells are relevant to study because the exposure route of indoor 
microbial compounds is through inhalation. Although alveolar epithelial cells (paper II) are 
biologically plausible actors in an immune response, the presumably most important immune 
cells in lung tissues are the alveolar macrophages. Monocytes resemble macrophages with regard 
to most innate immune responses, except for the superior phagocytic capacity of the macrophages 
and differences in the magnitude of inflammatory cytokine production (Losa-García et al., 1999). 
We used the adherent cell fraction of blood monocytes isolated from PBMC to simulate 
macrophage activity with regard to cytokine production (papers III and IV).  
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4.2  Findings and implications 
4.2.1 The ”relevant dose” question – from culture wells to damp buildings 
Exposure effects to environmental microbes must be assumed to vary. Besides the 
concentration of inhaled microbes and their products, other factors such as the thresholds for 
activation of various cell types and differences in the individual susceptibility to the exposure 
substance are of importance.  
The presence of mycotoxins in damp buildings is presumably of importance, but as the 
concentration of inhaled toxins is highly uncertain, human health effects are difficult to evaluate. 
In fact, it may not be possible to predict concentrations of inhaled mycotoxins due to lack of 
validated investigation methods. Perhaps the most uncertain method is to detect mycotoxin 
exposure by determining the presence of a fungal species known to be responsible for toxin 
production. Different fungi may favour certain building materials and the growth conditions for a 
particular fungal strain, in order to produce toxins, may differ. E.g. species of the fungal 
contaminant Chaetomium may produce the mycotoxin chaetoglobosin A at 50 µg/cm2 on 
wallpapered gypsum boards, but at the same time the quantities of mycotoxins isolated from 
Penicillium sp. may be low (Nielsen et al., 1999). Another method used to determine airborne 
mycotoxin exposure is to extract mycotoxins from fungal spores and fragments. This may, 
however, not be representative for the actual environmental toxin concentration if (i) the fungal 
strain is grown on standardised nutrition media as toxin production may be depleted at laboratory 
conditions, and (ii) the yield of toxin after extraction from the fungal strain may be low. In recent 
years, however, the methods used to detect mycotoxins from indoor environments, predominantly 
produced by Aspergillus sp. and Stachybotrys sp., have improved (Bloom et al., 2007).    
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On the basis of existing research on the topic, it cannot be ruled out that doses of 
mycotoxins that could affect inflammatory responses may be encountered in certain indoor 
exposure situations. Fungal spores and fragments may be effectively released from microbial 
growth on modern building materials, and especially during agitation or handling of the infected 
materials (Madsen et al., 2006). Moreover, for the mycotoxins investigated in this thesis, it has 
been shown that A. fumigatus grown on wallpapered gypsum boards can produce gliotoxin in 
concentrations of about 20 ng/cm2 (Nieminen et al., 2002), that would equal 2 µg mycotoxin/100 
cm
2
. Thus, it can be presumed that high enough mycotoxin doses to influence inflammatory 
responses can be encountered from relatively small areas with heavy mould growth on indoor 
materials, provided that the dose is quantitatively released and subsequently inhaled.  
Citrinin is a mycotoxin that has been isolated both from food, e.g. cheese (Kokkonen et 
al., 2005), and from indoor materials (Jarvis and Miller, 2005; Tuomi et al., 2000). Possibly, 
citrinin production is favoured on materials with high sucrose content, in contrast to cellulose 
content (El-Magraby and El-Maraghy, 1988). Thus, the production of citrinin on many cellulose 
based indoor materials may be restricted. However, it has been suggested that concentrations of 
citrinin in indoor environments may be up to 20 µg /g fungal biomass (Tuomi et al., 2000) 
suggesting that high enough doses to influence inflammatory responses could be relevant in 
certain settings.  
The water soluble extracellular polysaccharides, often called extracellular polymeric 
substances (EPS), are major components of most microbial cell walls including all kinds of fungi. 
The saccharides may contain monomers of different sugars such as mannose, fucose, glucose, 
galactose or arabinose and the production of the different sugars is highly dependent of the 
growth conditions of the microbe (Cho et al., 2001). EPS extracted from Aspergillus and 
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Penicillium isolates (EPS-Asp/Pen) have been used in immunoassays in order to detect 
environmental EPS as surrogates for fungal exposure (Chew et al., 2001; Douwes et al., 1999). 
As mentioned, there may be several different saccharides and the amount of mannose polymers 
(as parts of the EPS) has not been reported.  
High concentrations of EPS in indoor environments have been suggested to correlate with 
increased building-related respiratory symptoms (Douwes et al., 1999). However, it has also been 
pointed out that increased EPS concentrations in indoor environments of e.g. farm children may 
be inversely related to asthma development (Ege et al., 2007). The conflicting reports may be due 
to lack of characterisation of the exposure agent or different methods used in the investigations. 
The latter study showed high variability of exposure effects between different countries, 
suggesting that confounding factors may be involved.  
A high variability in detected EPS concentrations has been observed particularly in damp 
buildings. Some authors have suggested that relative concentrations of EPS in settled house dust 
could be in the range between 25,000 and 50,000 U/g (Chew et al., 2001; Douwes et al., 1999; 
Douwes et al., 2006). It must be assumed that a variability of EPS concentrations in damp 
buildings is caused by various amounts of microbes present, especially fungi, but also the lack of 
standardised and validated methods for analysis and characterisation of these polysaccharides 
(and their biological activity) may lead to a high uncertainty with regard to the interpretation of 
findings.  
Glucan content of indoor settled house dust has been detected in various concentrations, 
e.g. about 22 mg/g (Gehring et al., 2001), about 1 mg/g (Chew et al., 2001) and about 0.6 mg/g 
(Douwes et al., 2000). Concentrations up to 300 μg glucan/mg dust have been detected in an 
occupational waste handling industry (Wouters et al., 2006). None of these studies provided 
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information about the molecular forms of the glucans detected, which presumably are highly 
different depending on environmental conditions (Sletmoen and Stokke, 2008).  
Only a few studies have addressed the glucan concentrations in bronchoalveolar lavage 
(BAL) fluids from individuals exposed to airborne fungi. Although increased glucan 
concentrations in BAL fluids (in the range from 200 to 2,500 pg/mL) have been measured along 
with enhanced pro-inflammatory cytokine release, this has only been investigated in patients 
diagnosed with the inflammatory lung disease farmer’s lung or in patients with acute eosinophilic
pneumonia (described as a variant of summer-type hypersensitivity pneumonitis) (Ashitani et al.,
2008; Kawayama et al., 2003). However, these findings suggest that increased concentrations of 
glucan in BAL fluids can be associated with the development of inflammatory lung diseases.     
It should be emphasised that the ability of different glucans to exert biological activity, 
i.e. modulate cytokine production, is dependent on that a sufficient amount of glucan molecules 
bind to cell surface receptors, and therefore on the administrated dose, molecular weight and 
branching, and conformation of the molecule (Okazaki et al., 1995; Sletmoen and Stokke, 2008; 
Falch et al., 2000). In order to identify the active component that presumably gives a particular 
biological effect, the sample should be well characterised and the number of interfering 
substances that may affect cellular responses should be minimised. These requirements are 
challenging when working with fungal glucan extracts, since small differences in the fungal 
genetics as well as environmental factors such as growth substrate, temperature and moisture 
could lead to differences in the sample composition. Also, the fact that glucans may interact with 
‘guest’ molecules, i.e. bind other molecules in the environment, complicates characterisation and 
the measurement of actual biological activity of the glucan sample. Hence, the diversity of 
glucans found in nature is a result of the diversity of structurally distinct molecules and 
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impurities. When used in research projects, this could lead to different conclusions when 
comparing results from different research groups (Brown and Gordon, 2003).  
Health effects of endotoxin exposure in indoor environments, and in particular in damp 
buildings, have been reported and as for the fungal products there are variable concentrations 
measured, e.g. in house dust samples in a range between 30,000 EU/g dust (Heinrich et al., 2003) 
and 60,000 EU/g dust (Douwes et al., 2006; Hines et al., 2000). In occupational settings, such as 
waste handling industries, bioaerosol concentration has shown to exceed conventional exposure 
limits (Dutch) (50-200 EU/m3 for inhaled endotoxin) (Wouters et al., 2006). Building-related 
symptoms associated with endotoxin exposure are overall similar to those of fungal exposure, 
especially upper and lower respiratory symptoms and headache (Park et al., 2006).  
Reports of modulation of inflammatory symptoms due to exposure to mixed microbial 
compounds such as environmental endotoxin (LPS) and glucan are few. However, it has been 
reported in an epidemiologically study that exposure to endotoxin may change the effect of 
fungal exposure (and vice versa), more specifically that lower respiratory symptoms are enhanced 
by a mixed endotoxin and fungal exposure (Park et al., 2006). This suggests that symptoms due 
to mixed exposure could be different, and may be enhanced, compared to symptoms from single 
compound exposure. However, the molecular mechanisms of glucans as biological response 
modifiers are not well understood, but may involve both activating and inhibitory pathways. 
Some authors have demonstrated inhibitory effects of mixed LPS and glucan exposure with 
regard to pro-inflammatory cytokine production (Soltys et al., 1999), thus supporting the findings 
in paper III. Also, it has been suggested that individuals exposed to organic dust when living at 
farms, presumably involving combined exposure of endotoxin and fungal glucan, could be 
protected against adult asthma (Douwes et al., 2007). On the other hand, another report concludes 
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that exposure to a farming environment is not always beneficial, but rather that e.g. pig-keeping 
farms constitute so-called “protective factors” (Ege et al., 2007). Further, and on a more general 
basis, in vivo observations indicate that microbial exposure effects and susceptibility for asthma 
development may be strongly regulated by genetic factors, such as the individual expression of 
TLR genes (Eder et al., 2004; Ege et al., 2006). Also, another recent study emphasise that genetic 
variations in the innate immunity gene expression could modulate the individual response to 
microbial agents and the susceptibility and development of atopy and asthma (Smit et al., 2007). 
In this context, it is tempting to suggest that the results presented in paper IV could reflect that 
reduced pro-inflammatory cytokine production in asthmatics may partly be regulated by the 
levels of circulating MBL that is presumably regulated by MBL genes. The possible associations 
between fungal exposure, individual MBL levels and asthma development remain to be 
elucidated.   
4.2.2 What do our findings tell us about the symptoms experienced in damp buildings? 
Findings in this thesis can partly explain some of the experienced non-allergic 
inflammatory symptoms in damp buildings. More specifically, results reported in paper I, II 
and III suggest that the mycotoxins citrinin or gliotoxin may act indirectly to support a pro-
inflammatory cytokine production and reduce anti-inflammatory cytokine production induced 
by LPS. Further, the mycotoxin citrinin in particular, increased oxidative stress mechanisms 
and this may support an inflammatory state of the cells.  
Reports of symptoms including irritation of mucous membranes and cough may be 
explained by a general sensitivity to particulate substances, including spores, and it seems 
plausible that inflammagenic compounds present on the inhaled bacteria, spores, fungal 
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fragments or other carrier substances would further enhance such irritation. Other symptoms 
of inflammatory processes, including headache, fever, nausea and fatigue, may be initiated by 
production of TNF-α in particular (Oshiro and Morris, 1997; Sanchez-Del-Rio and Reuter, 
2004). Yet, other symptoms are more difficult to relate directly to known specific or non-
specific cellular immune responses. Respiratory symptoms reported by means of damp 
buildings, especially by asthmatics, but the cellular mechanisms responsible for these 
symptoms are still inconclusive. Several factors of the innate and/or adaptive immune system 
may be involved (Eisenbarth et al., 2004). However, aggravation of inflammatory respiratory 
symptoms is likely to be related to pro-inflammatory cytokine production, both in normal and 
asthmatics. 
  
4.2.3 The role for mannose-binding lectin (MBL) in asthma and the asthmatic 
response to fungal exposure        
Although a strong correlation between fungal exposure and severity and aggravation 
of asthmatic disease has been reported (Denning et al., 2006; Zureik et al., 2002; O'Driscoll 
et al., 2005), the molecular mechanisms underlying the clinical symptoms in asthma due to 
fungal exposure are still not clarified.  
Among the genetically influenced immune modulating proteins of the innate immune 
system, MBL has emerged (Turner and Hamvas, 2000). Little is known about the role for 
MBL in immune responses to fungal exposure, but several aspects of MBL may be of 
importance. First, high levels of MBL have been implicated in the development and 
maintenance of airway hyper responsiveness (Hogaboam et al., 2004). Further, MBL is 
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capable of binding to fungi such as Candida albicans, Cryptococcus neoformans and A. 
fumigatus (Neth et al., 2000). Environmental bacteria are also recognised by MBL 
(Niedoszytko et al., 2007). Also, a role for MBL has been shown in the modulation of 
inflammatory cytokine production in monocytes, as discussed in paper IV. It seems that high 
physiological levels of MBL may inhibit or reduce pro-inflammatory cytokine production 
from monocytes/macrophages (Jack et al., 2001). However, the role for MBL in asthma, in 
the context of inhibition of TNF-α production, brings up conflicting theories. The fact that 
clinical symptoms of inflammation in both normal and asthmatic subjects is largely 
characterised by high systemic TNF-α production (Gaga et al., 2007), does not support a role 
for MBL in reducing TNF-α production. In allergic asthma, however, where the cytokine 
profile is skewed towards high IL-4, IL-5 and IL-13 production, mast cells seem to be an 
important source of TNF-α production (Nakae et al., 2007). This suggests that MBL may 
have a role in reducing TNF-α production from monocytes, but not from mast cells, and that 
the influence of MBL may be restricted to professional phagocytes. 
4.2.4 Implications for future practice and future research 
The cellular inflammatory response mechanisms responsible for symptoms in 
asthmatics due to fungal exposure need to be further elucidated. It is of particular interest to 
investigate the non-allergic inflammatory responses to fungal exposure in relation to MBL 
production. The fact that MBL may be an important modulator of inflammatory diseases 
could induce the hypothesis that certain individuals may be particularly susceptible for the 
development of asthmatic disease. Moreover, it may be of particular interest to explore if and 
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how specific fungal cell wall polysaccharides bind to MBL and whether this could affect the 
inflammatory response in asthma. 
In a more practical setting, it is of particular interest to further elucidate the role for 
mycotoxins in a fungal exposure situation. The fact that only a limited amount of reports have 
suggested that mycotoxins may be present in sufficient concentrations to affects immune 
responses in exposed individuals calls for further research on this topic. 
The most important issue, however, is to develop and improve methods used for the 
measurement of airborne mycotoxins and other fungal products. When increased knowledge 
of actual and relevant exposure doses is established, symptoms reported from exposed 
individuals in damp and mouldy buildings may better be related to cellular responses.
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4.3     Overall conclusions 
The mycotoxins studied may promote inflammatory responses by inhibiting 
production of anti-inflammatory cytokines at doses which do not inhibit pro-inflammatory 
cytokine production (paper I).  
The mycotoxin citrinin in particular reduces levels of the antioxidant glutathione 
which may enhance inflammatory responses related to oxidative stress in alveolar epithelial 
cells. Also, the mycotoxins studied may interfere with the production of the anti-
inflammatory cytokine TGF- β while not affecting pro-inflammatory cytokine/chemokine 
production (paper II). 
Interactions between microbial products (LPS and glucan in particular) can modulate 
TNF-α production from monocytes. These interactions cannot be predicted by the exposure 
to one substance at a time. These results may possibly explain some of the conflicting reports 
of combinatory exposures in damp buildings (paper III). 
Asthmatics produce lower levels of the pro-inflammatory cytokine TNF-α after 
fungal cell wall mannan exposure of monocytes. The autologous plasma concentration of 
mannan-binding lectin (MBL) may be relevant for the pro-inflammatory cytokine production 
in asthma (paper IV). 
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Abstract
Mould exposure has been associated with asthma and other inﬂammatory airway conditions. However, cellular effects of inhaled
mould components are not well understood. We hypothesised that host defence mechanisms, such as production of cytokines
(TGF1, IL-6 and IL-8) and the intracellular antioxidant glutathione (GSH), could be adversely affectedbydifferent concentrations of
mycotoxins. We studied the effects of citrinin and gliotoxin on lipopolysaccharide (LPS)-stimulated alveolar epithelial cells (A549).
Cytokines in cell culture supernatants were analysed by ELISA and levels of GSH were measured by colorimetric (absorbance)
determination.We found that GSH decreased in a dose- and time-dependent manner when cells were exposed to citrinin in particular.
TGF1 was moderately reduced at low mycotoxin concentrations but elevated at higher sub-toxic concentrations. A tendency for
an inverse relationship between TGF1 and GSH levels was observed. IL-6 and IL-8 were not signiﬁcantly reduced at non-toxic
mycotoxin concentrations. Thus, reduced epithelial GSH and TGF1 levels combined with elevated IL-6 and IL-8 levels may result
in increased pro-inﬂammatory activity during mycotoxin exposure. We suggest that this mechanism can contribute to inﬂammation
in mould exposure.
© 2006 Elsevier Ireland Ltd. All rights reserved.
Keywords: Indoor moulds; Mycotoxins; Inﬂammation; Oxidative stress; Cytokines
1. Introduction
An association between indoor mould exposure and
inﬂammatory airway responses such as asthma has
frequently been reported (Douwes and Pearce, 2003;
Norba¨ck et al., 1999; Peat et al., 1998; Zock et al., 2002).
 This work was done at the Department of Cancer Research and
Molecular Medicine.
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fax: +47 73 59 88 01.
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The exposure situation is complicated by the presence of
several different compounds produced by moulds, along
with the presence of bacterial endotoxins (Thorn, 2001).
Indoor moulds may be a source of potentially inﬂam-
magenic, allergenic and toxic compounds, e.g. cell wall
polysaccharides such as-glucans, enzymes such as glu-
coamylases, allergenic proteins, and also several volatile
organic compounds (MVOC’s) that could act additively
or synergistically to induce and increase inﬂammation
and immune responses (Beijer et al., 2003; Kreja and
Seidel, 2002; Mari et al., 2003; Rylander and Rong-
Hwa, 2000). Some studies indicate that adverse health
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effects in mouldy buildings could in part be related
to toxic metabolites (mycotoxins) produced by moulds
(Bunger et al., 2005; Fischer and Dott, 2003; Jarvis and
Miller, 2005). Several mycotoxins have been associated
with health effects seen in humans due to mould expo-
sure (Bennett and Klich, 2003). Common mould genera
such as Aspergillus and Penicillium are frequently iso-
lated from water-damaged buildings and, depending on
growth conditions, they may produce mycotoxins. One
mycotoxin that is often produced by A. fumigatus on
water damaged building materials is the immunosup-
pressive compound gliotoxin (Nieminen et al., 2002;
Schulz et al., 2004; Watanabe et al., 2004). Citrinin,
which is known to be nephrotoxic, has been isolated from
mouldy buildingmaterialswith growth ofPenicillium sp.
and Aspergillus sp. among other mould species (Tuomi
et al., 2000).
Host defence mechanisms against inhaled microbes
include production of cytokines and chemokines by
several different cell types including epithelial cells
in the airway mucosa. The normal regulation of an
immune reaction is dependent on the balance between
pro-inﬂammatory mediators, such as IL-1, TNF-, IL-
6, IL-8 and IL-12, and regulatory cytokines such as
IL-10 and TGF1. In this study, we explored the
effects of mycotoxins on production of IL-6, IL-8 and
TGF1. IL-6 is a pleiotropic pro- and anti-inﬂammatory
cytokine involved in cell proliferation, antibody pro-
duction and acute-phase protein formation. Depletion
of IL-6 may also be important during pro-apoptotic
processes (Hodge et al., 2002). IL-8 is a chemokine
generally important in chemotaxis during inﬂamma-
tion. Production of transforming growth factor beta
1 (TGF1) is important in the development of sev-
eral chronic lung diseases, including asthma (Howell
and McAnulty, 2006; Redington et al., 1997; Tillie-
Leblond et al., 1999). Altered TGF1 production has
also been associated with chronic inﬂammatory pul-
monary diseases with the induction of oxidative stress
in alveolar epithelial cells (Mastruzzo et al., 2002).
Normal host defence mechanisms include the constant
production of relatively high amounts of the antioxidant
glutathione (GSH). GSH is present in all mammalian
cells and provides reducing equivalents for the redox-
reaction catalysed by the reducing enzyme glutathione
peroxidase. During this process GSH becomes oxi-
dised glutathione (GSSG). The GSSG is then recycled
into GSH by glutathione reductase and 2-nicotinamide
adenine dinucleotide phosphate (NADPH). It has been
shown that adequate productionofGSHcontrols and reg-
ulates inﬂammatory processes in the lung (Rahman and
MacNee, 2000). Hence, alteration in alveolar GSH pro-
duction is recognised as a central feature of progressive
inﬂammatory lung diseases, such as asthma.
We hypothesised that mycotoxins may interfere with
the normal levels of GSH and the balance of cytokines
produced during inﬂammatory responses triggered by
LPS. The aim of this studywas to explorewhethermyco-
toxins affect the production of some of the cytokines
involved in lung inﬂammation (IL-6, IL-8 and TGF1)
and also whether oxidative stress occurred in alveolar
epithelial cells when they were exposed to mycotoxins.
2. Materials and methods
2.1. Experimental design
The human alveolar epithelial carcinoma cell line A549
(Lieber et al., 1976) was cultured with or without lipopolysac-
charide (LPS) to induce production of IL-6, IL-8 and TGF1.
After exposure to citrinin or gliotoxin, cytokine levels were
analysed in cell culture supernatants. Further, cell viability
was measured to provide information on whether or not LPS
and mycotoxins had cytotoxic effects in the concentrations
used. To investigate oxidative stress in cells when exposed to
mycotoxins, intracellular reducedglutathione levels (GSH) and
oxidised glutathione levels (GSSG) were determined.
2.2. Culture of alveolar epithelial cells
The cell line A549 (ATCC CCL-185) was obtained from
the American Type Culture Collection (Manassas, VA, USA)
and cultured at 37 ◦C and 5% CO2 in Ham’s F12K growth
medium with l-glutamine (Gibco Life Tech., Eggenstein, Ger-
many) supplemented with 10% heat-inactivated foetal bovine
serum (FBS) (EuroClone, Milano, Italy) and 0.5% gentamicin
(Gibco).
2.3. Mycotoxins
Citrinin fromPenicillium citrinum and gliotoxin fromGlio-
cladium virens (Sigma–Aldrich, Steinheim, Germany) were
dissolved in 96% ethanol and serially diluted in cell culture
medium as described below. The ﬁnal concentration of ethanol
in the cell culture experiments was maximum 1% (v/v) for the
highest mycotoxin concentrations.
2.4. Cell culture assay
A549 cells were adjusted to 105 cells/mL and 400L
was added into three separate 24-well culture plates (Costar,
Corning, NY, USA) for each of the mycotoxins. Cells were
allowed to rest overnight at 37 ◦C and 5% CO2. Then,
50L lipopolysaccharide (LPS) from Pseudomonas aerugi-
nosa (Sigma) was added to a ﬁnal concentration of 10g/mL.
The mycotoxins were added in concentrations ranging from 0
to 50g/mL citrinin and 0 to 100 ng/mL gliotoxin in dilution
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steps of 1:2. The exposed andnon-exposed cellswere incubated
for 0 h, 1 h, 6 h, 24 h, 48 h and 72 h (for GSH and viability anal-
ysis) or 48 h and 72 h (for cytokine and viability analyses). All
experiments were repeated on two (GSH) or three (cytokine)
different occasions.
2.5. Analysis of cytokines
A quantitative sandwich ELISA cytoset (BioSource
Europe, Nivelles, Belgium) was used for measurement of the
cytokines IL-6, IL-8 and TGF1 in cell culture supernatants
and the analysiswas performedaccording to themanufacturer’s
recommendations. Brieﬂy, 96-well ELISA plates (NUNC,
Roskilde, Denmark) were coated with murine monoclonal
anti-human IL-6 antibody, anti-human IL-8 antibody or anti-
multispecies TGF1 antibody. After addition of the cell culture
supernatants, incubation and washing, biotinylated murine
anti-IL-6 antibody, anti-IL-8 antibody or anti-TGF1 antibody
was added. Recombinant human IL-6, IL-8 and multispecies
TGF1 proteins were used as standards. After incubation,
HRP-streptavidine enzyme was added, followed by substrate
solution containing tetramethylbenzidine (Sigma). The optical
density was read in a microplate reader (BioRad, Hercules,
CA, USA) at 450 nm. Concentrations of cytokines were calcu-
lated from standards ranging from 1000 to 7.8 pg/mL (IL-6),
800 to 7.8 pg/mL (IL-8) or 4000 to 7.8 pg/mL (TGF1) in
dilution steps of 1:2. The results are presented as mean and
standard deviation (S.D.) of duplicate ELISA samples (two
samples from each of three separate culture plates in each of
three independent experiments).
2.6. Cell viability testing
To investigate the time- and dose-dependent effects of the
mycotoxins on A549 cells, Alamar Blue dye (BioSource) was
used as recommended by the manufacturer. Cells were incu-
bated with increasing concentrations of mycotoxins (with or
withoutLPS) for 0 h, 1 h, 6 h, 24 h, 48 h and72 h (GSHanalysis)
or 48 h and 72 h (cytokine analysis). Cells in the culture plates
were spun down, and the cells were provided with fresh culture
media before 10%Alamar Blue dyewas added and the cultures
were incubated further for 3 h at 37 ◦C and 5% CO2. Change in
cell metabolic activity was registered as a colour change in the
wells. Aliquots of 100L were taken from cell culture super-
natants and added into 96-well plates (Costar), andﬂuorometric
determinations weremade in a Fluoroscan II plate reader (Lab-
systems, Stockholm, Sweden) at emission wavelength 590 nm
and excitation wavelength 544 nm. Cell viability after myco-
toxin/LPS exposure was calculated as percent of controls (cells
with no mycotoxin added).
2.7. GSH/GSSG assay
Analysis of GSH and GSSG levels was performed accord-
ing to a modiﬁed form of the Tietze method (Tietze, 1969)
by using the Bioxytech GSH/GSSG-412 kit (Oxis Research,
Portland, OR, USA) which utilises the change in colour devel-
opment during the reaction. The reaction rate is proportional to
the GSH or GSSG concentrations in each sample. Experiments
were performed according to the manufacturer’s recommenda-
tions, with slight modiﬁcations. Brieﬂy, cells were exposed to
mycotoxins (with or without LPS) as described above. After
0 h, 1 h, 6 h, 24 h, 48 h or 72 h incubation, cell culture plates
were centrifuged at 500× g for 5min and supernatants were
gently removed without removing unattached cells in the cell
culture. Then, 100L ice cold PBSwas added to the wells, and
additionally 10L of scavenger reagent (M2VP) was added to
the GSSG samples to scavenge GSH and prevent oxidation of
GSHandhence an overestimation ofGSSG in the samples. Cell
culture plates were then immediately frozen at −80 ◦C until
GSH/GSSG analysis. Before analysis, samples were thawed
for 2min, and 300L ice cold 5%metaphosphoric acid (MPA)
(Sigma) was added. Then, the samples were sonicated in the
cell culture plates for at least 15min keeping the water in the
sonicator cold by adding ice. The lysed cells weremixed gently
and the culture plates were centrifuged for 10min at 1000× g
and 4 ◦C before adding 50L of MPA extract (cell culture
supernatant) to 700L of ice-cold GSSG or GSH buffer pro-
vided with the kit. Final dilution of samples was 1:60. The
samples were kept on ice until ﬁnal preparation and analysis of
absorbance at 412 nm in a Hitachi U-2000 spectrophotometer
(Hitachi, Tokyo, Japan).
2.8. Data presentation and statistical analysis
Analysis of cytokines, GSH/GSSG and viability are pre-
sented as means and standard deviation (S.D.) from two
(GSH/GSSG with viability testing) or three (cytokine with
viability testing) separate experiments. Statistical analysis
was performed using unpaired two-tailed Student’s t-test to
compare the exposed cultures (LPS/mycotoxin) with the non-
exposed cultures (no mycotoxin). For comparison of relative
TGF1 and GSH curves, a two-way analysis of variance of
means (ANOVA) was used. A probability value of 0.05 or less
was considered statistically signiﬁcant in all experiments.
3. Results
3.1. Cell viability
Cell viability after mycotoxin exposure was deter-
mined by the Alamar Blue dye method. The mycotoxins
generally reduced cell viability in a dose- and time-
dependent manner both for citrinin and gliotoxin, as
seen in Figs. 1 and 2. Citrinin at 50g/mL reduced cell
viability to 80% of control values after 6 h incubation
(Fig. 1C) and after 24 h incubation, viabilitywas reduced
to approximately 40% of control values (Fig. 1D). The
majority of cells did not survive 50g/mL citrinin after
72 h incubation as cell viability dropped to approxi-
mately 20% of control values (Fig. 1F). Cell viability
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Fig. 1. GSH levels (A412) and cell viability of A549 cells after incubation for 0 h (A), 1 h (B), 6 h (C), 24 h (D), 48 h (E) and 72 h (F) with or without
Pseudomonas aeruginosa LPS (10g/mL) and different concentrations of citrinin. GSH values are given as net absorbance (subtraction of blanks)
at 412 nm and are the means±S.D. of two separate experiments. (*) Signiﬁcant decreased GSH levels compared to control (P< 0.05). ( )
GSH (without LPS); ( ) GSH (with LPS); () viability (without LPS); () viability (with LPS).
was reduced to approximately 40% after 6 h (Fig. 2C)
and to approximately 20% after 24 h and 48 h when
cells were incubated with 100 ng/mL gliotoxin (Fig. 2D
and E). In contrast, cell viability was not signiﬁcantly
reduced after incubation with 100 ng/mL gliotoxin for
72 h (Fig. 2F). Exposure to mycotoxin with LPS in the
cell culture medium did not reduce cell viability to a
greater extent than mycotoxin without LPS. Ethanol (as
solvent for the mycotoxins) in the concentrations used
(maximum 1% (v/v)) did not exert any signiﬁcant effect
on cell viability (results not shown).
3.2. GSH production and cell viability
A time-dependent increase in relative GSH lev-
els in non-exposed control cultures was observed
(Figs. 1 and 2). With increasing doses of mycotoxins,
GSH levels were reduced. Notably, for citrinin, a signiﬁ-
cant reduction of GSH occurred at concentrations below
toxic doses at incubation times 48 h and 72 h (Fig. 1E and
F), while this was not seen for gliotoxin (Fig. 2E and
F). GSH levels were not signiﬁcantly affected by LPS
alone. The oxidised form of glutathione (GSSG) was not
increased with decreasing GSH levels, and GSSG levels
were not elevated above baseline levels at anymycotoxin
concentrations (results not shown). Ethanol (as solvent
for the mycotoxins) in the concentrations used (maxi-
mum 1% (v/v) and maximum 72 h incubation) did not
exert any signiﬁcant effect on GSH levels (results not
shown).
3.3. Cytokine production and cell viability
Production of IL-6, IL-8 and TGF1 from A549
cells was induced by the presence of P. aeruginosa LPS
(Figs. 3 and 4). In contrast, LPS from Escherichia coli
(serotype 026:B6) did not induce detectable amounts
of IL-6, IL-8 or TGF1 (results not shown). None of
the LPS preparations induced detectable production of
TNF-, IL-12, IL-10 or IL-4 fromA549 cells (results not
shown).Mycotoxin exposurewithout LPSdid not induce
cytokine production above baseline levels at the concen-
trations used (Fig. 3; results not shown for IL-6/IL-8
analysis in Fig. 4).
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Fig. 2. GSH levels (A412) and cell viability of A549 cells after incubation for 0 h (A), 1 h (B), 6 h (C), 24 h (D), 48 h (E) and 72 h (F) with or without
P. aeruginosa LPS (10g/mL) and different concentrations of gliotoxin. GSH values are given as net absorbance (subtraction of blanks) at 412 nm
and are the means±S.D. of two separate experiments. (*) Signiﬁcant decreased GSH levels compared to control (P< 0.05). ( ) GSH (without
LPS); ( ) GSH (with LPS); () viability (without LPS); () viability (with LPS).
3.3.1. TGFβ1
Although not consistently statistically signiﬁcant,
TGF1 levels seemed to be overall reduced at the
lower mycotoxin concentration range (below 0.8g/mL
citrinin and below 1.6 ng/mL gliotoxin) as shown in
Fig. 3. A tendency to increased TGF1 levels was con-
sistently observed at higher mycotoxin concentrations
(1.6–12.5g/mL citrinin and 3.1–50 ng/mL gliotoxin)
in the presence of LPS. Citrinin at 25g/mL (with
and without LPS) and 48 h incubation reduced TGF1
abruptly along with a small reduction of cell viabil-
ity to approximately 90% of control values. Citrinin
at 50g/mL signiﬁcantly reduced TGF1 levels both
after 48 h and 72 h along with reduction of cell via-
bility to about 40% and 20% of control values. The
highest concentration of gliotoxin (100 ng/mL) did
not reduce TGF1, in contrast to the ﬁndings with
citrinin.
3.3.2. IL-6 and IL-8
The concentration of IL-6 was reduced after 48 h
incubation when cells were exposed to 25g/mL cit-
rinin in the presence of LPS while cell viability was
reduced to about 90% (Fig. 4A). The highest concen-
tration of citrinin (50g/mL) reduced IL-6 levels with
a simultaneous reduction of cell viability to approx-
imately 40%. A similar tendency was observed at
72 h incubation, although not statistically signiﬁcant.
Gliotoxin at 50 ng/mL and 48 h incubation reduced
IL-6 levels signiﬁcantly (Fig. 4B), while gliotoxin at
the highest concentration after 72 h incubation did
not reduce IL-6 levels signiﬁcantly. IL-8 was signif-
icantly reduced after 72 h incubation with 25g/mL
citrinin, with a simultaneous reduction of cell viabil-
ity to approximately 80% (Fig. 4A), while 50g/mL
citrinin reduced IL-8 along with loss of cell viabil-
ity to about 40% of control values after 48 h and to
about 20% after 72 h incubation. Gliotoxin reduced IL-
8 production signiﬁcantly at 100 ng/mL after 48 h and
caused reduction in cell viability to approximately 40%
of control values (Fig. 4B). IL-8 was not reduced after
72 h incubation with any of the gliotoxin concentra-
tions, and also cell culture viability was maintained after
72 h.
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Fig. 3. TGF1 production and cell viability of A549 cells after incubation for 48 h or 72 h with or without P. aeruginosa LPS (10g/mL) and
different concentrations of citrinin (A and B) or gliotoxin (C and D). Values are the means±S.D. of three separate experiments. (*) Signiﬁcantly
decreased TGF1 levels compared to control (P< 0.05). (#) Signiﬁcantly increased TGF1 levels compared to control (P< 0.05). ( ) TGF1
(with LPS); ( ) TGF1 (without LPS); () viability (with LPS); () viability (without LPS).
3.4. Inverse co-variation between TGFβ1 and GSH
Fig. 5 shows the relative (compared to control) lev-
els of GSH and TGF1 after 48 h or 72 h incubation
of A549 cells with mycotoxin and LPS. A tendency
to an inverse co-variation between GSH and TGF1
can be observed. Comparison of GSH curves with
TGF1 curves at citrinin concentration steps identical
to those used in the GSH assay, shows a signiﬁcant
difference between the curves at concentrations from
0.8 to 12.5g/mL (Fig. 5A and B). In the lower
concentration range (below 0.8g/mL citrinin), rela-
tive GSH levels were higher than relative amounts of
TGF1. The highest dose of citrinin (50g/mL) reduced
both GSH and TGF1 corresponding to decreased
cell viability. At 0.8–3.1g/mL citrinin, TGF1 levels
increased while GSH levels were decreased. Gliotoxin
did not affect GSH and TGF1 levels in the same
manner as citrinin. However, concentrations from 0.8
to 100 ng/mL gliotoxin seemed to increase TGF1
slightly (Fig. 5C and D), while GSH was not sig-
niﬁcantly affected by gliotoxin in this concentration
range.
4. Discussion
The mycotoxins gliotoxin and citrinin are produced
by common indoormoulds such asAspergillus andPeni-
cillium. These toxins have been shown to exhibit diverse
cellular effects, including cytotoxicity. The aim of this
study was to investigate the dose- and time-dependent
effects of citrinin and gliotoxin on the alveolar epithelial
cell line A549. Both citrinin and gliotoxin are known to
be toxic to various types of cells, and the cytotoxicity is
known to be due to apoptosis (Johannessen et al., 2005;
Waring et al., 1988; Yu et al., 2006; Zhou et al., 2000).
Apoptosis is an efﬁcient cellular mechanism to remove
damaged cells without causing sustained organ inﬂam-
mation. However, very high doses of these mycotoxins
will kill A549 cells directly by necrosis (unpublished
observations). Our hypothesis was that non-cytotoxic
concentrations of mycotoxins would affect intracellular
oxidant/antioxidant balance mechanisms and/or inter-
fere with inﬂammatory cytokine responses triggered by
LPS.
We found that the mycotoxins, in a dose- and time-
dependentmanner, decreased cell viability ofA549 cells.
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Fig. 4. IL-6 and IL-8 production and cell viability of A549 cells after
incubation for 48 h or 72 h with P. aeruginosa LPS (10g/mL) and
different concentrations of citrinin (A) or gliotoxin (B). Values are the
means±S.D. of three separate experiments. (*) Signiﬁcant reduction
compared to control (P< 0.05). ( ) IL-8 (48 h); ( ) IL-8
(72 h); ( ) IL-6 (48 h); ( ) IL-6 (72 h); () viability (48 h);
() viability (72 h).
After 6 h incubation, viability was reduced to 80% (cit-
rinin) and to approximately 40% (gliotoxin) when the
highest mycotoxin concentrations were used (50g/mL
citrinin or 100 ng/mL gliotoxin). After 72 h incubation,
50g/mL citrinin reduced cell viability to about 20%
of control values. Gliotoxin at 100 ng/mL seemed not to
be completely cytotoxic to A549 cells as we observed a
population of surviving cells after 72 h incubation. Dou-
bling time ofA549 cells is about 22 h (Lieber et al., 1976)
and we suggest that some cells after 72 h may have pro-
liferated, hence the maintenance of cell culture viability.
Possibly, this indicates some heterogeneity of the cell
line, with selection of gliotoxin-resistant variants.
We now tested if oxidative stress could be induced by
sub-toxic doses of themycotoxins. The levels of reduced
glutathione (GSH) and oxidised glutathione (GSSG)
were measured in relation to dose and time of exposure
for both mycotoxins. Under normal conditions, cellu-
lar redox- and defence-mechanisms include action of
regulatory enzymes keeping the oxidised form of glu-
tathione (GSSG) at low intracellular levels, while the
reduced form of glutathione (GSH) is produced in high
amounts (Rahman and MacNee, 2000). GSH depletion
is in some cases associated with GSSG elevation and this
is known to occur in response to some oxidative stim-
uli, such as H2O2, while GSH depletion in parallel with
unchanged and low GSSG levels have been described as
a response to other oxidative stimuli, such as cigarette
smoke condensate (CSC) (Rahman et al., 1995). First,
we observed a time-dependent increase of GSH levels
in the non-exposed control cultures, suggesting a time-
dependent increase of cell density. Then, we found that
citrinin, in a dose- and time-dependent manner, reduced
GSH levels before any extensive loss of cell viability,
while GSH reduction by gliotoxin was minimal before
loss of cell viability. Neither of the mycotoxins caused
elevated GSSG levels above baseline. Reactive oxygen
species (ROS) may cause direct oxidising of GSH and
form GSSG, while other types of oxidative agents may
form conjugates with GSH, and temporarily prevent re-
synthesis of GSH rather than elevating the intracellular
GSSG levels (Rahman et al., 1995). We speculate that
GSH may counteract the damaging effects of citrinin
by forming GSH-citrinin conjugates, although this has
to be conﬁrmed by further studies. Such formation of
GSH-citrinin conjugates has to our knowledge not been
described in the literature. Recently, it has been sug-
gested that apoptosis in human promyelocytic leukemia
cells after citrinin exposure is not associated with forma-
tion of cellular oxidative stress (Yu et al., 2006). Here,
we report that citrinin signiﬁcantly reduce the antioxi-
dant glutathione at sub-toxic doses, therefore we suggest
that induction of oxidative stress may be part of citrinin
cytotoxicity in alveolar epithelial cells.
Gliotoxin exists naturally in an oxidised form and
cellular uptake is a glutathione-dependent mechanism,
as shown in a murine tumour cell line (Bernardo et
al., 2003). The toxin is rapidly reduced by GSH after
cellular internalisation. However, induction of reactive
oxygen species (ROS) followed by apoptosis have been
observed inmany cell types, including renal cells at a rel-
atively high dose of gliotoxin (1200 ng/mL) (Zhou et al.,
2000). We observed no decrease in GSH levels at con-
centrations below 100 ng/mL gliotoxin, indicating that
no extensive oxidative stress occurs in gliotoxin-exposed
alveolar epithelial cells below toxic concentrations.
We wanted to test if the mycotoxins affected the
release of cytokines from epithelial cells triggered by
LPS. First, we tested the ability of LPS from E. coli
(serotype 026:B6) to trigger cytokine release, and then
LPS from P. aeruginosa. No cytokine production was
detected with LPS from E. coli. We found that LPS from
P. aeruginosa at a relatively high dose (10g/mL) stimu-
latedA549 cells to release IL-6, IL-8 andTGF1, but not
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Fig. 5. Relative GSH (♦) and TGF1 () production from A549 cells after incubation for 48 h or 72 h with P. aeruginosa LPS (10g/mL) and
different concentrations of citrinin (A and B) or gliotoxin (C and D). Statistical calculations were performed by two-way ANOVA.
TNF-, IL-12, IL-10 or IL-4. Previously, similar results
on the ability of different LPS preparations to stimulate
A549 cells have been reported (Koyama et al., 2000).
It is likely that different bacterial LPS have somewhat
different potentials to cause inﬂammatory reactions in
various cells and organs. Thus, P. aeruginosa, being a
pathogen of the lung, may be more likely than E. coli to
induce LPS-induced inﬂammatory reactions in alveolar
epithelial cells.
We found that the pleiotropic cytokine TGF1 and
the pro-inﬂammatory cytokines IL-6 and IL-8 were
affected by increasing mycotoxin doses, although IL-6
and IL-8 largely remained elevated at non-toxic concen-
trations. IL-6 was slightly reduced at sub-toxic doses
of 25g/mL citrinin and at 50 ng/mL gliotoxin after
48 h incubation, while IL-8 remained elevated until the
highest mycotoxin concentrations. Although not consis-
tently signiﬁcant, we found that TGF1 was slightly
reduced at the lower mycotoxin concentration range,
while a tendency to increased levels was observed at
higher mycotoxin doses. Asthma, and other inﬂamma-
tory diseases, is characterised by high levels of bio-active
TGF1 in vivo (Redington et al., 1997), but also by
even higher levels of pro-inﬂammatory cytokines (Tillie-
Leblond et al., 1999).
Regulation of TGF1 expression in the cell still
remains largely unclear. Epithelial TGF1 production
may not depend on the induction of pro-inﬂammatory
mediators such as TNF-, IL-1 and IL-8, but rather
TGF1 production may involve pro-inﬂammation inde-
pendent pathways (Kwong et al., 2004). Interestingly,
we found that there seems to be an inverse co-
variation between levels of GSH and production of
TGF1 at sub-toxic mycotoxin concentrations. This
effect was most clearly seen with citrinin. At low cit-
rinin concentrations (<0.8g/mL) GSH levels were
relatively higher than TGF1. At higher citrinin con-
centrations (from 3.1 to 12.5g/mL citrinin) TGF1
was elevated along with a corresponding decrease
in GSH.
Previously, it has been reported that TGF1 is a
potent inhibitor of GSH, and that GSH depletion in
A549 is executed by TGF1 by transcriptional down-
regulation of the enzyme responsible forGSH formation,
-glutamylcysteine synthetase (Arsalene et al., 1997;
Jardine et al., 2002). Although it seems that citrinin
reduces GSH in parallel to elevated TGF1 production
in our experiments, it cannot be ruled out that TGF1
maybe the true inhibitor ofGSH. In this context, elevated
TGFlmay be the response to sub-toxic doses of citrinin,
while depletion ofGSHwill be the indirect consequence.
However, this cannot explain the situation after gliotoxin
exposure as non-toxic doses did not deplete GSH levels
signiﬁcantly, in spite of elevated TGF1 production.
Our experiments showed that increased TGF1
production occurred at relatively high mycotoxin con-
centrations, although well below concentrations causing
extensive cell death. Previously, it has been shown that
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human bronchial epithelial cells that underwent apopto-
sis up-regulated TGF1, while IL-6 was down-regulated
(Hodge et al., 2002). Cytotoxicity in A549 cells is likely
to proceed by apoptosis and the elevated TGF1 lev-
els and the decreased IL-6 observed may have been
pro-apoptotic effects of themycotoxins.However, at pro-
longed incubation times, the tested sub-toxic exposure
doses did not cause further reduction of cell viability, as
would have been expected with an induction of apopto-
sis, but rather cell viability remained constant after 48 h
and 72 h incubation.
The mechanisms behind health effects caused by
inhalation of toxigenic mould spores are yet to be further
investigated. In this study we demonstrated that citrinin,
but not gliotoxin, reduced glutathione levels in A549
cells at non-toxic concentrations.An inverse co-variation
between TGF1 and GSH levels was also demonstrated.
Further, the levels of IL-6 and IL-8 were largely main-
tained in the non-toxic concentration range.
The levels of airbornemycotoxins that readilymay be
inhaled inmouldy environmentsmust be assumed to vary
depending on the amount of toxigenic moulds present.
However, in a case of favourable growth of toxigenic
moulds, we speculate that the observations in this study
may reﬂect an ability of gliotoxin and citrinin in particu-
lar, to render human alveolar epithelial cells susceptible
to inﬂammatory trigger agents in the environment, such
as other mould components and bacterial LPS. Also,
a susceptibility to environmental oxidative agents may
develop. We suggest that this may facilitate asthma and
other inﬂammatory lung diseases experienced by indi-
viduals in mouldy environments.
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